Orexo AB’s wholly owned U.S. subsidiary, Orexo US Inc., has been awarded $8 million in funding by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services. The funding will support the development of OX390, an intranasal rescue medication for adulterated opioid overdoses.  The award is structured in five stages and is valued at up to $50.9 million that could b...